Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.59
NAS:PCRX's Cash-to-Debt is ranked lower than
58% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. NAS:PCRX: 1.59 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:PCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72  Med: 1.59 Max: No Debt
Current: 1.59
Equity-to-Asset 0.56
NAS:PCRX's Equity-to-Asset is ranked lower than
61% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:PCRX: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:PCRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.73  Med: 0.43 Max: 0.59
Current: 0.56
-0.73
0.59
Piotroski F-Score: 4
Altman Z-Score: 6.15
Beneish M-Score: -3.08
WACC vs ROIC
15.19%
-19.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -11.59
NAS:PCRX's Operating Margin % is ranked lower than
78% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. NAS:PCRX: -11.59 )
Ranked among companies with meaningful Operating Margin % only.
NAS:PCRX' s Operating Margin % Range Over the Past 10 Years
Min: -325.77  Med: -126.13 Max: 3.8
Current: -11.59
-325.77
3.8
Net Margin % -13.73
NAS:PCRX's Net Margin % is ranked lower than
79% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. NAS:PCRX: -13.73 )
Ranked among companies with meaningful Net Margin % only.
NAS:PCRX' s Net Margin % Range Over the Past 10 Years
Min: -300.62  Med: -133.77 Max: 0.75
Current: -13.73
-300.62
0.75
ROE % -17.15
NAS:PCRX's ROE % is ranked lower than
79% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. NAS:PCRX: -17.15 )
Ranked among companies with meaningful ROE % only.
NAS:PCRX' s ROE % Range Over the Past 10 Years
Min: -558.91  Med: -54.49 Max: 0.95
Current: -17.15
-558.91
0.95
ROA % -9.72
NAS:PCRX's ROA % is ranked lower than
77% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. NAS:PCRX: -9.72 )
Ranked among companies with meaningful ROA % only.
NAS:PCRX' s ROA % Range Over the Past 10 Years
Min: -82.83  Med: -46.36 Max: 0.52
Current: -9.72
-82.83
0.52
ROC (Joel Greenblatt) % -21.85
NAS:PCRX's ROC (Joel Greenblatt) % is ranked lower than
76% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. NAS:PCRX: -21.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:PCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -251.5  Med: -116.71 Max: 8.96
Current: -21.85
-251.5
8.96
3-Year Revenue Growth Rate 42.30
NAS:PCRX's 3-Year Revenue Growth Rate is ranked higher than
94% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. NAS:PCRX: 42.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:PCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -66.9  Med: -5.5 Max: 80.4
Current: 42.3
-66.9
80.4
3-Year EBITDA Growth Rate -34.20
NAS:PCRX's 3-Year EBITDA Growth Rate is ranked lower than
94% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. NAS:PCRX: -34.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:PCRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.2  Med: -65.15 Max: -34.2
Current: -34.2
-70.2
-34.2
3-Year EPS without NRI Growth Rate -19.10
NAS:PCRX's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. NAS:PCRX: -19.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:PCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.6  Med: -65.6 Max: -19.1
Current: -19.1
-68.6
-19.1
GuruFocus has detected 1 Warning Sign with Pacira Pharmaceuticals Inc $NAS:PCRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:PCRX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

PCRX Guru Trades in Q2 2016

Jim Simons 34,800 sh (New)
Steven Cohen 281,236 sh (New)
Ron Baron 56,351 sh (+247.61%)
Mariko Gordon 1,076,724 sh (+11.79%)
Ken Fisher 6,197 sh (unchged)
Lee Ainslie Sold Out
» More
Q3 2016

PCRX Guru Trades in Q3 2016

Mariko Gordon 1,220,044 sh (+13.31%)
Ken Fisher 6,282 sh (+1.37%)
Steven Cohen Sold Out
Jim Simons 24,800 sh (-28.74%)
Ron Baron 21,921 sh (-61.10%)
» More
Q4 2016

PCRX Guru Trades in Q4 2016

Ron Baron 24,255 sh (+10.65%)
Jim Simons 25,200 sh (+1.61%)
Ken Fisher Sold Out
Mariko Gordon 1,219,642 sh (-0.03%)
» More
Q1 2017

PCRX Guru Trades in Q1 2017

Ken Fisher 6,257 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with PCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:RDUS, OTCPK:SWPIF, NAS:SUPN, OTCPK:TWMJF, OTCPK:EVTCY, NAS:EGRX, NAS:HZNP, OTCPK:GNMLF, NAS:ENDP, NAS:PAHC, OTCPK:KHTRF, NAS:IRWD, NYSE:DPLO, NAS:SGYP, OTCPK:CSWYF, NAS:MNTA, NAS:IPXL, OTCPK:NPPNY, OTCPK:TZHGF, NAS:FLXN » details
Traded in other countries:82P.Germany,
Headquarter Location:USA
Pacira Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development, commercialization and manufacture of proprietary pharmaceutical products for use in hospitals and ambulatory surgery centers.

Pacira Pharmaceuticals is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and commercialization of pharmaceutical products, primarily for use in hospitals and ambulatory surgery centers. The company focuses its product candidates within the United States, and intends to out-license commercialization rights for other territories. Pacira aims to retain significant control over the development process and commercial execution for its product candidates.

Guru Investment Theses on Pacira Pharmaceuticals Inc

Baron Funds Comments on PaciraPharmaceuticals - Jan 18, 2017

Other companies we favor have wrapped intellectual property around an already proven pharmaceutical to create a new, protected franchise. The risk of not receiving approval for such products is significantly lower than for a typical bio-pharma investment. An example is PaciraPharmaceuticals, Inc. (NASDAQ:PCRX), whose FDA-approved medication is comprised of the pain killer bupivacaine combined with proprietary IP called Depo-Foam that enables its timed release. The product is appealing as it can in many cases eliminate the need for post-operative opiates and result in a shorter hospital stay.



From Baron Discovery Fund's Investing in Earlier Stage Small Cap Growth Companies January 2017.



Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals - Aug 10, 2016

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells an injectable drug for local post-surgical analgesia (localized pain relief) called EXPAREL. In the fourth quarter of 2015, Pacira reached a very favorable resolution with the FDA concerning certain issues which had previously impeded its ability to market its drug to hospital customers. We re-established our investment in the company in the third quarter of 2015 as it appeared from public reports that the company was making significant progress on this front (and the FDA removed the warning letter from its site in September). Shares have been weak in the second quarter of 2016 as Pacira has not yet seen a re-acceleration in the growth of the drug (management has always guided to a late 2016 effect). In our opinion, Pacira still retains its large multi-billion dollar market opportunity, and we should start to see accelerating revenues by year-end.



From Baron Discovery Fund's second quarter 2016 commentary.





Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals Inc. - May 19, 2016

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells a drug for local surgical analgesia (an anesthetic) called EXPAREL. At the end of the third quarter of 2015, Pacira received a favorable resolution of certain FDA issues, and we re-established our investment at the lower levels caused by the prior regulatory uncertainty. In our opinion, shares were down in the first quarter due to the general negative industry dynamics around pharmaceutical companies.



From the Baron Global Advantage Fund first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals Inc. - Feb 25, 2016

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells a long-lasting pain medication called EXPAREL. This is an approved drug for local surgical analgesia (an anesthetic) that can be used for a multitude of soft tissue and orthopedic procedures. Ultimately, we believe that Pacira will obtain a nerve block indication for the drug as well. Effectively, Pacira has taken a generic drug called bupivacaine (under use for decades) and wrapped it with a special time release coating that allows analgesic effects to last for up to three days instead of just hours. This saves money for the health care system by allowing for earlier release of patients and much lower use of dangerous opioid pain killers. This wrapper technology can be used for other drugs, and the company is developing a number of these which could bring additional upside to valuation. We were prior owners of Pacira, but sold the investment at much higher levels when we grew concerned about regulatory issues with the FDA that cropped up at the end of 2014. Shares dropped considerable after that. By the end of the third quarter, we anticipated a favorable resolution of these issues after the FDA removed the warning letter from its website (a highly unusual event), and we re-established our investment at the lower levels caused by the regulatory uncertainty. In the fourth quarter, Pacira resolved all of its marketing issues with the FDA via a formal agreement. This could allow for accelerated growth in 2016. Run rate sales of EXPAREL are now about $250 million and the market could be worth billions. Pacira has the potential for years of continued growth.



From Baron Discover Fund's fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Pacira Pharmaceuticals Inc

MonoSol Rx Appoints James S. Scibetta to Board of Directors
Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference
Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide

Collaboration will develop and standardize evidence-based, low-opioid strategies across Trinity Health's 22 states to benefit people and communities
PARSIPPANY, N. J. and LIVONIA, Mich., March 16, 2017 (GLOBE NEWSWIRE) -- Trinity Health, one of the largest hospital systems in the nation, and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced they will collaborate to develop an alternative approach to opioids for pain management.This collaboration intends to demonstrate the way health care systems and the pharmaceutical industry can work together to improve patient care and address a serious global problem that affects the health of individuals as well as communities.In collaboration, Trinity Health and Pacira will work to improve the overall patient-recovery experience and decrease the threat of long-term opioid risks which include misuse, abuse, and addiction. In doing so, they will also improve the economics of acute care and create new procedure-specific enhanced recovery and pain protocols that, when appropriate, will include using less risky pharmaceutical alternatives to opioids. Together, the organizations will also develop both physician- and patient-facing educational materials and generate quality improvement data that tracks their successes and progress reducing the use of opioids for pain management. This data will also guide next steps in developing and testing other protocols and products.“The health care industry must strive to eliminate painkiller addiction and its often tragic endings," said Paul Conlon, Pharm.D, J.D., and senior vice president of Clinical Quality and Patient Safety for Trinity Health. "We are pleased to be working with Pacira to develop a more people-centered approach for pain management across the many diverse communities we serve."Under the terms of the collaborative agreement, Trinity Health and Pacira teams will identify patient populations who would most benefit from opioid minimization strategies in hospitals. They will then develop protocols and training for procedure-specific enhanced recovery. Each approach will aim to reduce or replace opioids that are commonly used to manage postsurgical pain. â€œWe are excited and proud to collaborate with Trinity Health on this joint commitment to reducing reliance on opioids as the first line of defense for managing acute pain,” said Dave Stack, chairman and chief executive officer of Pacira. “By working collectively to develop, disseminate, and educate on these enhanced recovery protocols, and thus reducing exposure to debilitating and costly opioid-related adverse events or longer-term societal burden, we are truly advancing patient care.”Beyond the unwanted and potentially life-threatening adverse events associated with opioid use, research continues to uncover the connection between their introduction in the hospital setting and the overall societal opioid burden.A recent JAMA Internal Medicine article highlighted that for opioid-naive patients, many surgical procedures are associated with an increased risk of chronic opioid use in the postsurgical period;1 perhaps more startling, a recent national survey revealed that 1 in 10 patients admit they’ve become addicted to or dependent on opioids after being exposed to these powerful medications following an operation.2Adding further validity to the importance and impact of these collaborative opioid-sparing protocols is the element of patient preference. A 2014 study uncovered that more than half of postsurgical patients prefer a non-opioid option,3 and a national survey conducted in 2016 found many patients have indicated they are delaying surgery due to fear of taking opioids to manage their pain.2According to a 2016 analysis of health care claims, opioids also significantly contribute to health care system costs.4 The study showed that the national aggregated dollar value of charges related to opioid-related diagnoses increased more than 1,000 percent from 2011 ($32.4 million) to 2015 ($445.7 million), and private payers’ average costs for patients abusing or dependent on opioids was almost $16,000 more per patient than the average cost per patient across all patients’ claims.4Additionally, the U.S. Centers for Disease Control and Prevention recently shared their findings on the high societal cost of the opioid epidemic, which burdens the U.S. economy with an estimated total of $78.5 billion a year.5About Trinity HealthTrinity Health is one of the largest multi-institutional Catholic health care delivery systems in the nation, serving diverse communities that include more than 30 million people across 22 states. Trinity Health includes 93 hospitals, as well as 120 continuing care programs that include PACE, senior living facilities, and home care and hospice services. Its continuing care programs provide nearly 2.5 million visits annually. Based in Livonia, Mich., and with annual operating revenues of $16.2 billion and assets of $23.4 billion, the organization returns almost $1 billion to its communities annually in the form of charity care and other community benefit programs. Trinity Health employs about 97,000 full-time employees, including 5,300 employed physicians. Committed to those who are poor and underserved in its communities, Trinity Health is known for its focus on the country's aging population. As a single, unified ministry, the organization is the innovator of Senior Emergency Departments, the largest not-for-profit provider of home health care services — ranked by number of visits — in the nation, as well as the nation’s leading provider of PACE (Program of All Inclusive Care for the Elderly) based on the number of available programs. For more information, visit www.trinity-health.org. You can also follow @TrinityHealthMI on Twitter.About Pacira                                                                           Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.Forward Looking StatementsAny statements in this press release about our future expectations, plans, outlook and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL and our other products; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications; the outcome of the U.S. Department of Justice inquiry; our plans to evaluate, develop and pursue additional DepoFoam-based product candidates; clinical trials in support of an existing or potential DepoFoam-based product; our plans to continue to manufacture and provide support services for our commercial partners who have licensed DepoCyt(e); our commercialization and marketing capabilities; our and Patheon UK Limited’s ability to successfully and timely construct dedicated EXPAREL manufacturing suites; and other factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.References                                      Sun EC, Darnall B, Baker LC, Mackey S. JAMA Intern Med. Published online July 11, 2016. doi:10.1001/jamainternmed.2016.3298.Wakefield Research on behalf of Pacira Pharmaceuticals. Opioid Addiction and Dependence After Surgery is Significantly Higher than Previously Known. 2016.Gan TJ, et al. Curr Med Res Opin. 2014;30(1):149-160.FAIR Health White Paper. The Impact of the Opioid Crisis on the Healthcare System. September 2016. Florence, Curtis S. PhD, et al. Medical Care. 2016;54(10): 901-906. 
Media Contacts:
Trinity Health
Eve Pidgeon, (313) 605-1026
[email protected]

Pacira Pharmaceuticals, Inc.
Susan Mesco, (908) 391-8283
[email protected]

Coyne Public Relations
Alyssa Schneider, (973) 588-2270
[email protected]

Read more...
Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption and Postsurgical Pain in Patients Undergoing Total Knee Arthroplasty
Multicenter randomized study serves as unequivocal evidence of EXPAREL as an opioid minimizing agent in a complex and painful surgical procedureProtocol’s best practice infiltration technique for the use of EXPAREL will be focus of educational programs at American Academy of Orthopaedic Surgeons Annual MeetingPARSIPPANY, N.J. , March 14, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) in patients undergoing total knee arthroplasty (TKA) achieved statistical significance for its co-primary endpoints for postsurgical pain and opioid reduction. EXPAREL also achieved statistical significance for certain key secondary endpoints, including time to first opioid use and the percentage of patients who did not require any opioid to treat their postsurgical pain. The company is completing its analyses of additional secondary endpoints. The results from the study will be submitted as a series of publications in the peer-reviewed medical literature later this year.The co-primary efficacy endpoints were the area under the curve (AUC) of the pain intensity scores measured on a visual analog scale (VAS) from 12 to 48 hours after surgery and the total opioid consumption expressed as morphine equivalents from zero to 48 hours after surgery. The EXPAREL group achieved a statistically significant reduction in pain scores compared to the group who did not receive EXPAREL (p=0.0381). Additionally, patients who received EXPAREL consumed significantly fewer opioids than patients who did not receive EXPAREL during the 48 hours that followed surgery (p=0.0048).Sixteen centers participated in this trial with 139 patients randomized to an EXPAREL-based or a bupivacaine-based multimodal pain regimen of oral acetaminophen, celecoxib and pregabalin.  In addition, all patients received intravenous tranexamic acid at the beginning of surgery or intra-operatively.The study showed the EXPAREL group achieved statistically significant differences compared to the group who did not receive EXPAREL for the following key secondary endpoints:The percentage of patients who were opioid-free through 48 hoursThe average time to first use of an opioid rescue medication“The operating room is the gateway to opioid abuse and places patients at serious risk for addiction and dependence,” said Dave Stack, chairman and chief executive officer of Pacira. “The results of this study provide further evidence that EXPAREL effectively reduces, and in some cases, eliminates the use of opioids while providing prolonged postsurgical pain relief to patients undergoing complex and painful knee replacement surgery with a simple inexpensive multimodal design. A recent survey determined that one in 10 opioid naïve patients are opioid dependent six months after opioid-driven postsurgical pain management – we believe EXPAREL can play a critical role in taking on this national issue.”1This Phase 4 study was a multicenter, randomized, double-blind, controlled, parallel group study. Patients were randomized to receive local infiltration analgesia with 266 mg of EXPAREL admixed with bupivacaine and expanded in volume to 120 mL (20 mL EXPAREL vial admixed with 20 mL standard bupivacaine 0.5% and expanded with 80 mL normal saline) to local infiltration analgesia with bupivacaine expanded in volume to 120 mL (20 mL standard bupivacaine 0.5% and expanded with 100 mL normal saline).  Investigators administered study drug using six 20 mL prefilled syringes.To support optimal and replicable outcomes in TKA, this study used a standardized infiltration protocol designed by experienced clinicians to define best practice technique for administering EXPAREL. Key features of the infiltration protocol include volume expansion to ensure full coverage of the nerve fibers responsible for sending pain signals to the brain, admixing with free bupivacaine to provide sufficient immediate pain relief, and a clear definition of the sites for infiltration and administration technique to ensure adequate coverage of the impacted nerve fibers.  Pacira and its partner, DePuy Synthes companies of Johnson and Johnson, are supporting a number of educational programs for best practice EXPAREL technique in orthopedic procedures. At the American Academy of Orthopaedic Surgeons Annual Meeting taking place in San Diego March 14-18, the companies will host innovative virtual reality experiences for clinicians to enhance their infiltration technique based on the protocol from the Phase 4 study of EXPAREL in TKA. About Pacira
                                                                                                  
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.About EXPAREL®EXPAREL (bupivacaine liposome injectable suspension) is currently indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired period of time. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain score with up to a 45 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at http://www.exparel.com/hcp/pdf/EXPAREL_Prescribing_Information.pdf.
Important Safety InformationEXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.Please see the full Prescribing Information for more details available at: http://www.exparel.com/hcp/pdf/EXPAREL_Prescribing_Information.pdf.
Forward Looking Statements
Any statements in this press release about our future expectations, plans, outlook and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL and our other products; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications; the outcome of the U.S. Department of Justice inquiry; our plans to evaluate, develop and pursue additional DepoFoam-based product candidates; clinical trials in support of an existing or potential DepoFoam-based product; our plans to continue to manufacture and provide support services for our commercial partners who have licensed DepoCyt(e); our commercialization and marketing capabilities; our and Patheon UK Limited’s ability to successfully and timely construct dedicated EXPAREL manufacturing suites; and other factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.References1. “Volleyball Legend Gabrielle Reece on Knee Replacement, Managing Pain, Olympics and More.” USA Today, 28 September 2016.
Company Contact:
Pacira Pharmaceuticals, Inc.
Susan Mesco, (973) 451-4030
[email protected]

Media Contact:
Coyne Public Relations
Alyssa Schneider, (973) 588-2270
[email protected]

Read more...
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference

PARSIPPANY, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its management team is scheduled to present at the Barclays Global Healthcare Conference at 10:15 a.m. ET on Thursday, March 16, 2017, in Miami.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date. About Pacira                                                                            Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact:
Pacira Pharmaceuticals, Inc.
Susan Mesco, (973) 451-4030
[email protected]

Read more...
Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375% Convertible Senior Notes due 2022

PARSIPPANY, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the pricing of $300 million aggregate principal amount of convertible senior notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).  Pacira also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $45 million aggregate principal amount of notes.  The sale of the notes to the initial purchasers is expected to settle on March 13, 2017, subject to customary closing conditions, and is expected to result in approximately $290 million of net proceeds to Pacira after deducting fees and estimated offering expenses payable by Pacira (assuming no exercise of the initial purchasers’ option to purchase additional notes).
Pacira intends to use a portion of the net proceeds to exchange approximately $112 million aggregate principal amount of its existing 3.25% convertible senior notes due 2019 (the “2019 Notes”) for a combination of cash and shares of Pacira common stock to be completed concurrently with the offering (the “Note Exchanges”). In connection with the Note Exchanges, Pacira expects to pay approximately $113 million in cash, which includes accrued interest, and issue approximately 2.4 million shares of its common stock, to settle such exchanges. The remaining net proceeds will be used for general corporate purposes, including working capital, research and development expenditures and the license or acquisition of complementary products and/or technologies. The notes will be general unsecured senior obligations of Pacira and will mature on April 1, 2022, unless earlier repurchased, redeemed or converted in accordance with their terms. The notes will bear interest at a fixed rate of 2.375% per year, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2017. Prior to the close of business on the business day immediately preceding October 1, 2021, the notes are convertible at the option of the holders only under certain conditions. On or after October 1, 2021, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their notes at their option, irrespective of these conditions.  Pacira will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. The conversion rate will initially be 14.9491 shares of common stock per $1,000 principal amount of notes, subject to adjustment in certain circumstances.  This represents an initial conversion price of approximately $66.89 per share, representing a 37.5% conversion premium over the closing price of $48.65 per share of Pacira common stock on March 7, 2017. On or after April 1, 2020, Pacira may redeem for cash all or part of the notes under certain circumstances at a redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling any note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the notes) with respect to that note, in which case the conversion rate applicable to the conversion of that note, if it is converted in connection with the redemption, will be increased in certain circumstances. The offering of the notes is being made to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and the shares of Pacira common stock, if any, issuable upon conversion of the notes have not been and will not be registered under the Securities Act or any state securities laws, and, unless so registered, the notes and such shares may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, or the solicitation of any sale, of any securities in any jurisdiction in which such offer, solicitation or sale is unlawful. About Pacira Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.   Forward Looking Statements Certain of the statements made in this press release, such as those, among others, relating to our expectations regarding the completion of the offering of the notes, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may” and similar expressions, constitute forward-looking statements.  Actual results or developments may differ materially from those projected or implied in these forward-looking statements.  Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not we will be able to raise capital through the offering of the notes, the final terms of the offering of the notes, market and other conditions, the satisfaction of customary closing conditions related to the proposed offering and the impact of general economic, industry or political conditions in the United States or internationally.  There can be no assurance that we will be able to complete the offering of the notes on the anticipated terms, or at all. Additional risks and uncertainties relating to the offering of the notes, Pacira and our business are discussed in the “Risk Factors” section of our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in other filings that we periodically make with the SEC.  In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and, as such, we anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Contact:
Susan Mesco
(973) 451-4030
[email protected]

Read more...
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of Convertible Senior Notes

PARSIPPANY, N.J., March 06, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).  Pacira also intends to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $45 million aggregate principal amount of notes.    
The terms of the notes, including the interest rate, initial conversion rate and other terms, will be determined by negotiations between Pacira and the initial purchasers of the notes. Pacira intends to use a portion of the net proceeds to enter into privately negotiated agreements with certain holders of its 3.25% convertible senior notes due 2019 (the “2019 Notes”) to exchange their 2019 Notes for a combination of cash and shares of Pacira common stock. The remaining net proceeds will be used for general corporate purposes, including working capital, research and development expenditures and the license or acquisition of complementary products and/or technologies. This offering is being made to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and the shares of Pacira common stock, if any, issuable upon conversion of the notes have not been and will not be registered under the Securities Act or any state securities laws, and, unless so registered, the notes and such shares may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, or the solicitation of any sale, of any securities in any jurisdiction in which such offer, solicitation or sale is unlawful. About Pacira Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Forward-Looking Statements Certain of the statements made in this press release, such as those, among others, relating to our expectations regarding the completion of the proposed offering, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may” and similar expressions, constitute forward-looking statements.  Actual results or developments may differ materially from those projected or implied in these forward-looking statements.  Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not we will be able to raise capital through the proposed offering, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed offering and the impact of general economic, industry or political conditions in the United States or internationally.  There can be no assurance that we will be able to complete the proposed offering on the anticipated terms, or at all. Additional risks and uncertainties relating to the proposed offering, Pacira and our business are discussed in the “Risk Factors” section of our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in other filings that we periodically make with the SEC.  In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and, as such, we anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Contact:
Susan Mesco
(973) 451-4030
[email protected]


Read more...
Baron Funds Comments on PaciraPharmaceuticals Guru stock highlight
Other companies we favor have wrapped intellectual property around an already proven pharmaceutical to create a new, protected franchise. The risk of not receiving approval for such products is significantly lower than for a typical bio-pharma investment. An example is PaciraPharmaceuticals, Inc. (NASDAQ:PCRX), whose FDA-approved medication is comprised of the pain killer bupivacaine combined with proprietary IP called Depo-Foam that enables its timed release. The product is appealing as it can in many cases eliminate the need for post-operative opiates and result in a shorter hospital stay. Read more...
Baron Funds Comments on Pacira Pharmaceuticals Guru stock highlight
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells an injectable drug for local post-surgical analgesia (localized pain relief) called EXPAREL. In the fourth quarter of 2015, Pacira reached a very favorable resolution with the FDA concerning certain issues which had previously impeded its ability to market its drug to hospital customers. We re-established our investment in the company in the third quarter of 2015 as it appeared from public reports that the company was making significant progress on this front (and the FDA removed the warning letter from its site in September). Shares have been weak in the second quarter of 2016 as Pacira has not yet seen a re-acceleration in the growth of the drug (management has always guided to a late 2016 effect). In our opinion, Pacira still retains its large multi-billion dollar market opportunity, and we should start to see accelerating revenues by year-end. Read more...
Baron Funds Comments on Pacira Pharmaceuticals Inc. Guru stock highlight
Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells a drug for local surgical analgesia (an anesthetic) called EXPAREL. At the end of the third quarter of 2015, Pacira received a favorable resolution of certain FDA issues, and we re-established our investment at the lower levels caused by the prior regulatory uncertainty. In our opinion, shares were down in the first quarter due to the general negative industry dynamics around pharmaceutical companies. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 149.25
PCRX's Forward PE Ratio is ranked lower than
99% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. PCRX: 149.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 8.12
PCRX's PB Ratio is ranked lower than
84% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. PCRX: 8.12 )
Ranked among companies with meaningful PB Ratio only.
PCRX' s PB Ratio Range Over the Past 10 Years
Min: 3.47  Med: 9.94 Max: 73.42
Current: 8.12
3.47
73.42
PS Ratio 6.37
PCRX's PS Ratio is ranked lower than
72% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. PCRX: 6.37 )
Ranked among companies with meaningful PS Ratio only.
PCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.39  Med: 11.74 Max: 30.31
Current: 6.37
0.39
30.31
Price-to-Free-Cash-Flow 203.90
PCRX's Price-to-Free-Cash-Flow is ranked lower than
93% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. PCRX: 203.90 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PCRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 130.39  Med: 413.82 Max: 1333.3
Current: 203.9
130.39
1333.3
Price-to-Operating-Cash-Flow 52.69
PCRX's Price-to-Operating-Cash-Flow is ranked lower than
84% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. PCRX: 52.69 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PCRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 33.69  Med: 82.73 Max: 909.74
Current: 52.69
33.69
909.74
EV-to-EBIT -59.81
PCRX's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. PCRX: -59.81 )
Ranked among companies with meaningful EV-to-EBIT only.
PCRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -776.7  Med: -11.4 Max: 543.4
Current: -59.81
-776.7
543.4
EV-to-EBITDA -103.01
PCRX's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. PCRX: -103.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
PCRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -200.5  Med: -10.7 Max: 856.9
Current: -103.01
-200.5
856.9
Current Ratio 5.42
PCRX's Current Ratio is ranked higher than
79% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. PCRX: 5.42 )
Ranked among companies with meaningful Current Ratio only.
PCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.69 Max: 5.42
Current: 5.42
0.87
5.42
Quick Ratio 4.72
PCRX's Quick Ratio is ranked higher than
77% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. PCRX: 4.72 )
Ranked among companies with meaningful Quick Ratio only.
PCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.32 Max: 4.72
Current: 4.72
0.75
4.72
Days Inventory 169.11
PCRX's Days Inventory is ranked lower than
74% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. PCRX: 169.11 )
Ranked among companies with meaningful Days Inventory only.
PCRX' s Days Inventory Range Over the Past 10 Years
Min: 31.07  Med: 75.65 Max: 230.95
Current: 169.11
31.07
230.95
Days Sales Outstanding 39.54
PCRX's Days Sales Outstanding is ranked higher than
81% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. PCRX: 39.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
PCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.85  Med: 40.64 Max: 67.76
Current: 39.54
29.85
67.76
Days Payable 24.90
PCRX's Days Payable is ranked lower than
88% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. PCRX: 24.90 )
Ranked among companies with meaningful Days Payable only.
PCRX' s Days Payable Range Over the Past 10 Years
Min: 20.45  Med: 44.4 Max: 246.51
Current: 24.9
20.45
246.51

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.70
PCRX's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. PCRX: -3.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -288.4  Med: -138 Max: -3.7
Current: -3.7
-288.4
-3.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 25.16
PCRX's Price-to-Net-Current-Asset-Value is ranked lower than
86% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. PCRX: 25.16 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PCRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 12.54  Med: 33.98 Max: 54.06
Current: 25.16
12.54
54.06
Price-to-Tangible-Book 10.28
PCRX's Price-to-Tangible-Book is ranked lower than
81% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. PCRX: 10.28 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.1  Med: 12.8 Max: 64.96
Current: 10.28
5.1
64.96
Price-to-Median-PS-Value 0.54
PCRX's Price-to-Median-PS-Value is ranked higher than
91% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. PCRX: 0.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 1.11 Max: 1.89
Current: 0.54
0.37
1.89
Earnings Yield (Greenblatt) % -1.69
PCRX's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. PCRX: -1.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.75  Med: 0.4 Max: 1.2
Current: -1.69
-1.75
1.2

More Statistics

Revenue (TTM) (Mil) $276.4
EPS (TTM) $ -1.01
Beta2.25
Short Percentage of Float11.81%
52-Week Range $29.95 - 62.23
Shares Outstanding (Mil)40.09

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 309 418 546
EPS ($) 0.29 1.94 3.80
EPS without NRI ($) 0.29 1.94 3.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
36.00%
Dividends per Share ($)
» More Articles for PCRX

Headlines

Articles On GuruFocus.com
MonoSol Rx Appoints James S. Scibetta to Board of Directors Apr 11 2017 
Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference Apr 03 2017 
4 Biotech Stocks to Watch Mar 22 2017 
Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide Mar 16 2017 
Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption Mar 14 2017 
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference Mar 13 2017 
Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375% Conver Mar 08 2017 
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of Con Mar 06 2017 
Baron Funds Comments on PaciraPharmaceuticals Jan 18 2017 
Investing in Earlier Stage Small Cap Growth Companies - Baron Discovery Fund Jan 18 2017 

More From Other Websites
Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US :... Apr 25 2017
Can Pacira Pharmaceuticals' Exparel Reduce Opioid Abuse? Apr 19 2017
Can Drugmakers Cure the Opioid Crisis? Apr 18 2017
Pacira Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PCRX) : April 17, 2017 Apr 17 2017
Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PCRX-US :... Apr 13 2017
Pacira Focuses on Lead Candidate Exparel's Label Expansion Apr 12 2017
MonoSol Rx Appoints James S. Scibetta to Board of Directors Apr 11 2017
Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference Apr 03 2017
Pacira (PCRX) Down 7.2% Since Earnings Report: Can It Rebound? Apr 03 2017
Anesthesia Can't Save This Biotech From Feeling Pain: Analyst Mar 23 2017
Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide Mar 16 2017
Why Pacira Pharmaceuticals Stock Is Already Up 56% This Year Mar 15 2017
Pacira Pharmaceuticals stock rises 2% on positive late-stage trial for opioid-reducing pain... Mar 14 2017
Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption... Mar 14 2017
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference Mar 13 2017
Is Pacira Pharmaceuticals' Balance Sheet Safe? Mar 09 2017
Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375%... Mar 07 2017
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of... Mar 06 2017
ETFs with exposure to Pacira Pharmaceuticals, Inc. : March 6, 2017 Mar 06 2017
Red-Hot Biotech Companies Highlight Jefferies Top Stocks to Buy Mar 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)